Moomoo AI 已提取核心信息
Alterity Therapeutics Limited, a development stage enterprise, has announced a security purchase plan (SPP Offer) to raise up to $2 million before costs. The SPP Offer includes the issue of up to 571,428,571 fully paid ordinary shares (SPP Shares) at $0.0035 per share, with one free-attaching option for each SPP Share issued, expiring on August 31, 2024 (Short Dated Options), and one free-attaching option for every three SPP Shares issued, expiring on August 31, 2026 (Long Dated Options). Eligible Shareholders may apply for a maximum of 8,571,429 SPP Shares ($30,000), with the offer opening on January 10, 2024, and closing on January 25, 2024. The SPP Offer is not underwritten and is available only to shareholders with registered addresses in Australia and New Zealand. The funds raised will support clinical trials, research efforts in neurodegenerative diseases, and general working capital. The SPP Shares and options are considered speculative investments.
Alterity Therapeutics Limited, a development stage enterprise, has announced a security purchase plan (SPP Offer) to raise up to $2 million before costs. The SPP Offer includes the issue of up to 571,428,571 fully paid ordinary shares (SPP Shares) at $0.0035 per share, with one free-attaching option for each SPP Share issued, expiring on August 31, 2024 (Short Dated Options), and one free-attaching option for every three SPP Shares issued, expiring on August 31, 2026 (Long Dated Options). Eligible Shareholders may apply for a maximum of 8,571,429 SPP Shares ($30,000), with the offer opening on January 10, 2024, and closing on January 25, 2024. The SPP Offer is not underwritten and is available only to shareholders with registered addresses in Australia and New Zealand. The funds raised will support clinical trials, research efforts in neurodegenerative diseases, and general working capital. The SPP Shares and options are considered speculative investments.
处于开发阶段的企业Alterity Therapeutics Limited宣布了一项证券购买计划（SPP报价），将在不计成本的情况下筹集高达200万美元的资金。SPP要约包括以每股0.0035美元的价格发行最多571,428,571股已全额支付的普通股（SPP股票），每发行一份将于2024年8月31日到期的免费附加期权（短期期权），以及每三股SPP股票的自由附加期权，将于2026年8月31日到期（远期期权）。符合条件的股东最多可以申请8,571,429股SP股票（合3万美元），要约将于2024年1月10日开始，并于2024年1月25日结束。SPP要约不承保，仅适用于注册地址在澳大利亚和新西兰的股东。筹集的资金将用于支持临床试验、神经退行性疾病的研究工作和一般营运资金。SPP股票和期权被视为投机性投资。
处于开发阶段的企业Alterity Therapeutics Limited宣布了一项证券购买计划（SPP报价），将在不计成本的情况下筹集高达200万美元的资金。SPP要约包括以每股0.0035美元的价格发行最多571,428,571股已全额支付的普通股（SPP股票），每发行一份将于2024年8月31日到期的免费附加期权（短期期权），以及每三股SPP股票的自由附加期权，将于2026年8月31日到期（远期期权）。符合条件的股东最多可以申请8,571,429股SP股票（合3万美元），要约将于2024年1月10日开始，并于2024年1月25日结束。SPP要约不承保，仅适用于注册地址在澳大利亚和新西兰的股东。筹集的资金将用于支持临床试验、神经退行性疾病的研究工作和一般营运资金。SPP股票和期权被视为投机性投资。
有用
没用